RPTX Repare Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 09 May 2022 Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day

   Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.

   A live webcast of the fireside can be accessed in the Investor section of the Company's website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company's website for 90 days.

   About Repare Therapeutics, Inc.

   Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of…

   View Full Article
2. 05 May 2022 Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

   Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500) monotherapy in solid tumors at 2022 AACR Annual Meeting

   Results demonstrated robust activity in ovarian cancer with a 75% CBR, 25% ORR and 35 weeks mPFS

   Results also show 43% CBR in solid tumors across genotypes and tumor types, potential best-in-class safety and tolerability, and encouraging data in other genotypes beyond ATM

   Publication of preclinical data in Nature demonstrated the potential of PKMYT1 inhibitor RP-6306 in tumors with CCNE1 amplification

   Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended…

   View Full Article
3. 20 April 2022 Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

   Data show PKMYT1 inhibition is a promising therapeutic target in CCNE1-amplified cancers

   RP-6306, a first-in-class, oral PKMYT1 inhibitor, is currently being evaluated in Phase 1 clinical trials

   Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306, a first-in-class small molecule candidate targeting PKMYT1, were published in Nature. SNIPRx^®, Repare's proprietary, genome-wide, CRISPR-based screening approach, was used to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.

   The article, entitled "CCNE1 amplification…

   View Full Article
4. 11 April 2022 Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

   RP-3500 shows robust activity in ovarian cancer demonstrating 75% CBR, with 25% ORR and mPFS of 35 weeks

   Updated monotherapy results show 43% CBR in solid tumors across genotypes, and potential best-in-class safety and tolerability

   Encouraging data in tumors harboring STEP² genes, including BRCA1/2 mutations, where RP-3500 monotherapy led to 43% CBR and mPFS of 15 weeks

   Company to host conference call today at 6:30 p.m. ET

   Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia…

   View Full Article
5. 08 April 2022 Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

   Comprehensive Phase 1 monotherapy data from the phase 1/2 TRESR trial will be presented at AACR on Monday, April 11, 2022 at 3:05 p.m. CT

   Company to host conference call on Monday, April 11, 2022 at 6:30 p.m. ET

   Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.

   The Company…

   View Full Article